Roche Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Roche Bundle
Download Your Competitive Advantage
Roche’s BCG Matrix snapshot shows which franchises are fueling growth and which need tough choices—think oncology stars versus legacy products that may be slipping. Want a clear map of market share, growth trajectories, and cash flow realities? Purchase the full BCG Matrix for quadrant-by-quadrant analysis, data-backed moves, and ready-to-use Word and Excel files that let you act fast and present with confidence.
Stars
Vabysmo (ophthalmology)
In 2024 Vabysmo (faricimab) continues fast-growing adoption in retinal disease, grabbing share in an anti-VEGF market that is still expanding following its 2022 approval and Q16W dosing label flexibility.
Its strong clinical profile and dosing flexibility are pulling demand across wet AMD and DMO, with real-world uptake accelerating as clinics adopt extended-interval regimens.
Keep the foot on the gas: invest in access, supply capacity, and real-world evidence generation to cement leadership and, if momentum holds, mature into a durable cash engine.
Tecentriq (immuno‑oncology)
Tecentriq (atezolizumab) holds leadership positions with approvals since 2016 in urothelial carcinoma and later expansions into NSCLC and triple‑negative breast cancer, yet label growth remains. The immuno‑oncology sector continues expansion and combination strategies (IMpower program) open new indications. Roche must sustain heavy clinical investment and targeted partnerships to defend share and scale the brand while demand is high.
Ocrevus (neuroscience, MS)
Ocrevus, approved since 2017 and available in over 90 countries, has delivered category-defining outcomes in MS with uptake in >300,000 patients globally and 2023 sales near $6.0bn, underpinning a healthy market and ongoing switch dynamics. Roche should double down on patient support and geographic expansion to lock in share and invest in lifecycle extensions to extend the runway.
Foundation Medicine (CGP/companion diagnostics)
Foundation Medicine, acquired by Roche for 2.4 billion USD in 2018, sits in the BCG Stars quadrant as CGP rides the still-growing precision‑oncology wave; its FDA‑approved FoundationOne CDx underpins strong pharma partnerships and payer engagement, reinforcing a durable moat and volume growth. Invest in assay breadth, faster turnaround, and expanding global reimbursement to sustain scale, which amplifies Roche’s oncology ecosystem.
- Tag: FDA‑approved companion diagnostic
- Tag: Roche ownership 2018, 2.4B USD
- Tag: Priorities — assay breadth, TAT, reimbursement
Core Lab Diagnostics (cobas systems)
Core Lab Diagnostics (cobas systems) remain a Star for Roche as high-throughput platforms show steady test‑menu expansion and new installs in 2024, with clinical volumes rebounding and reagent pull‑through accelerating year‑over‑year. Prioritizing service, uptime and menu leadership is critical to sustain placements and outpace rivals; today the portfolio is positioned to transition to a long‑term cash cow.
Q16W dosing fuels fast 2024 uptake; MS therapy >300,000 pts, ~$6.0bn sales
Vabysmo (faricimab) drives fast 2024 uptake in wet AMD and DMO with Q16W dosing flexibility and expanding clinic adoption.
Ocrevus remains category‑defining with >300,000 patients treated and ~$6.0bn sales in 2023, supporting continued MS market leadership.
Foundation Medicine (Roche 2018, $2.4bn) anchors CGP with FDA‑approved FoundationOne CDx and growing pharma partnerships.
cobas core lab platforms show rising installs and reagent pull‑through in 2024.
| Asset | 2023/24 KPI | Priority |
|---|---|---|
| Vabysmo | Q16W uptake 2024 | Access & RWE |
| Ocrevus | >300k pts; ~$6.0bn sales (2023) | Support & lifecycle |
| Foundation Med | Acq $2.4bn (2018) | Assay & reimbursement |
| cobas | 2024 rising installs | Service & menu |
What is included in the product
Detailed Word Document
BCG analysis of Roche's portfolio: Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page Roche BCG Matrix mapping each unit to a quadrant — clears portfolio clutter and speeds C‑suite decisions.
Cash Cows
Herceptin/Perjeta franchise (oncology)
Herceptin/Perjeta remains a cash cow for Roche with a massive installed base and strong clinician familiarity, though global HER2 market growth has plateaued and biosimilar uptake has eroded originator volumes in many markets. The franchise continues to generate meaningful free cash flow, supporting R&D and next-gen assets. Focus on pricing optimization, defending high-value segments (adjuvant/metastatic combinations) and portfolio mix management. Milk efficiently and reallocate surplus into next-generation oncology pipelines.
MabThera/Rituxan (immunology/oncology)
MabThera/Rituxan remains a large, mature Roche franchise with stable but slow volume growth; 2023 sales were roughly USD 3.5 billion as biosimilar uptake dampened expansion. Profitability stays solid despite mounting competitive pressure, with gross-margin resilience supporting cash generation. Management emphasizes cost discipline, tighter channel execution and selective tender wins, recycling cash to fund higher-upside pipeline bets.
Tissue Diagnostics (Ventana)
Tissue Diagnostics (Ventana) is embedded in pathology workflows with sticky instruments and consumables, driving high recurring revenue; Roche Diagnostics reported mid-single-digit sales growth in 2024. Volumes are mature and predictable with attractive margins; incremental menu additions and automation (including digital pathology integrations) improve throughput. Maintain service excellence and harvest cash from the installed base.
Diabetes Care (Accu‑Chek)
Diabetes Care (Accu‑Chek) is a broad-footprint cash cow for Roche in 2024, delivering steady, predictable cash flows while category growth remains modest and fiercely competitive; margins benefit from scale and strong brand trust. Keep operations lean, defend retail/clinic channels, streamline SKUs, and redirect cash to higher-growth platforms.
- Scale-driven margins
- Modest market growth
- Protect core channels
- SKU rationalization
- Fund growth bets
Centralized PCR menus (non‑COVID)
Centralized PCR menus (non‑COVID) represent established test panels with steady lab demand; growth in 2024 was incremental rather than explosive, driven by routine infectious disease and oncology workflows. Reagent pull‑through is sustained via Roche installed base and contracting; operational focus should be productivity, uptime and cash generation.
- Installed base: core revenue engine
- 2024: steady pull‑through, mid‑single‑digit volume growth
- Priority: maximize uptime, optimize contracts
Defend pricing, cut SKUs, reinvest cash - steady growth in oncology and diagnostics.
Herceptin/Perjeta: large cash generator despite HER2 market plateau and biosimilar erosion; continue pricing focus and reinvestment. MabThera/Rituxan: mature franchise with solid margins; biosimilars trimmed volumes (2023 sales ~USD 3.5bn). Ventana diagnostics and centralized PCR: mid-single-digit growth in 2024 with high recurring consumables pull‑through. Accu‑Chek: steady cash flow, defend channels and streamline SKUs.
| Product | 2024 signal | Priority |
|---|---|---|
| Herceptin/Perjeta | Plateau/biosimilars | Price/defend segments |
| MabThera/Rituxan | Stable margins | Cost discipline |
| Ventana/PCR | Mid-single-digit growth | Uptime/contracts |
| Accu‑Chek | Steady cash | SKU/retain channels |
Preview = Final Product
Roche BCG Matrix
The Roche BCG Matrix file you’re previewing is the exact document you’ll receive after purchase. No watermarks, no demo text—just a fully formatted, analysis-ready report tailored for strategic clarity. Once bought, the full file is immediately downloadable and editable for presentations or planning. Designed by strategy experts, it’s ready to use with no surprises or revisions needed.
Dogs
Legacy COVID-19 testing (PCR/antigen)
Legacy COVID-19 PCR/antigen testing volumes have fallen over 90% from the 2021 peak by 2024, with ASPs and channel pricing collapsing and cash generation shrinking to negligible levels, tying up manufacturing capacity. Priority is to minimize exposure: repurpose lines to higher-margin diagnostics, exit low-margin pockets and avoid costly turnarounds that erode cash.
Older small‑molecule oncology tails
Older small‑molecule oncology tails are patent‑expired, competing in crowded classes and delivering low single‑digit margins by 2024, often breaking even only after discounts and promotion. SKU and geography rationalization is required to cut distribution and marketing waste. Prioritize divestment or sunset of nonstrategic molecules to redeploy R&D and commercial spend to innovative pipelines.
Non‑core OTC/legacy hospital products
Non‑core OTC and legacy hospital products sit in a low‑growth, limited strategic‑fit segment with weak market share, becoming a management attention sink that drags resources from core diagnostics and oncology franchises. Management should prune the portfolio, redeploy capital to high‑growth RD pipelines and diagnostics, and retain only SKUs needed to satisfy bundled contract obligations. Prioritize divestment, licensing or selective discontinuation to free margins and R&D spend.
Late‑stage programs with repeated readout misses
Late-stage programs with repeated readout misses consume high spend and have very low probability of success; Roche spent about CHF 13.4 billion on R&D in 2024, so continuing low‑signal Phase III projects risks locking large capital into likely failures.
Each additional Phase III typically costs hundreds of millions (industry median Phase III spend ~USD 200–500 million), creating a capital trap and clear opportunity cost versus reallocating to higher-probability assets.
Strategy: stop, partner out, or kill quickly and redeploy resources to winners in the portfolio to maximize ROI and pipeline productivity.
- High spend: Roche R&D ~CHF 13.4bn (2024)
- Phase III cost: ~USD 200–500m
- Action: stop, out-license, or terminate
- Priority: concentrate capital on top-performing assets
Standalone pen‑and‑strip niches under heavy price pressure
Standalone pen-and-strip niches face heavy price pressure and eroding reimbursement; Commoditization leaves little brand leverage for Roche and Diabetes Care, which reported ~CHF 1.8bn sales in 2023 and saw margin compression into 2024 as payers push lower unit prices. Roche should reduce footprint, automate supply, and exit segments where margins fail to meet corporate hurdle rates.
- Commoditized segments
- Eroding reimbursement
- Little brand leverage
- Reduce footprint & automate
- Exit if margins below hurdle
Exit COVID >90% decline, trim CHF 1.8bn diabetes, refocus CHF 13.4bn R&D
Dogs: legacy COVID testing volumes down >90% vs 2021 by 2024, ASPs collapsed; older oncology tails patent‑expired with low single‑digit margins; non‑core OTC/hospital SKUs and commoditized diabetes strips (Diabetes Care ~CHF 1.8bn 2023) tie up cash; stop/partner/divest—redeploy against CHF 13.4bn R&D (2024) and avoid USD200–500m Phase III drains.
| Item | Metric | Action |
|---|---|---|
| COVID testing | Volumes -90% (2024) | Exit/repurpose |
| Diabetes strips | Sales CHF 1.8bn (2023) | Shrink/automate |
| R&D burden | CHF 13.4bn (2024); Phase III USD200–500m | Stop/partner |
Question Marks
Next‑gen Alzheimer’s/neurology assets
Next‑gen Alzheimer’s/neurology assets sit in Question Marks: category growth is high given 55 million people living with dementia worldwide and dementia costs exceeding USD 1 trillion annually, while CLARITY AD showed a 27% slowing with lecanemab, yet Roche’s commercial share remains nascent. Clinical risk (ARIA, variable efficacy) and real‑world access/reimbursement hurdles persist. If pivotal signals strengthen, scale up pivotal trials, tightly link diagnostics (amyloid PET/plasma NfL) and accelerate launch readiness and payer strategy. If not, cut exposure and reallocate capital to higher‑conviction assets.
Gene/cell therapy collaborations
Question Marks: Gene/cell therapy collaborations sit in a rapidly growing field where Roche holds low current share; global cell and gene therapy market is forecasting ~28% CAGR (2024 forecasts) and multibillion potential by 2030. Programs are capital intensive with uncertain timelines, forcing selective doubling down where platform data de‑risks. Partnering or out‑licensing where strategic fit is thin preserves Roche's CHF 14.6bn R&D firepower.
Digital diagnostics & NAVIFY platform
Digital diagnostics and NAVIFY sit in a fast-growing clinical decision support market forecast at ~11% CAGR to 2028, but enterprise penetration remains low. Monetization models (subscription, per-case, outcome-linked) are still evolving; Roche should invest to scale pilots into enterprise deals and tighten ROI proof. If uptake stalls, narrow focus to highest-value NAVIFY modules to protect margins.
Point‑of‑care molecular (new placements)
Point‑of‑care molecular is a Question Mark for Roche: demand for rapid, high‑accuracy testing beyond COVID rose in 2024 with the POC molecular market cited at ~9% CAGR to 2030, but Roche share varies by region and remains underpenetrated where hardware adoption lags. Priorities: fund placements, expand assay menu, and lock payer coverage rapidly; if pull‑through stalls, shift assays to centralized channels.
- Fund placements: prioritize capital for instrument rollout
- Menu: add high‑volume respiratory/GI panels
- Payer: secure reimbursement within 12–18 months
- Pivot: drive centralized lab uptake if site adoption < target
Ophthalmology pipeline beyond Vabysmo
Ophthalmology beyond Vabysmo sits in a growing category—global neovascular AMD/DME patient pool ~196 million in 2020 with anti‑VEGF market >$8 billion annually—yet Roche assets remain pre‑inflection with small share; clinical differentiation requires robust head‑to‑head and durability data. Prioritize accelerated pivotal trials and real‑world data capture; invest to convert into Stars or out‑license if midline signals persist.
- Accelerate pivots: shorten timelines to readouts
- RWD: implement registries and claims linkage
- Go/No‑Go: invest if superiority/durability demonstrated
- Out‑license: pursue partnerships if differentiation is marginal
Target Alzheimer's (55M; >USD1T) and ~28% gene/cell growth to protect CHF14.6bn R&D
Question Marks: high-growth areas (Alzheimer’s, gene/cell, NAVIFY, POC, ophthalmology) with low Roche share; burden/data: 55M dementia, >USD1T cost, lecanemab 27% slowing; gene/cell CAGR ~28% (2024 forecasts); prioritize select scale-ups, diagnostics linkage, payer plans or divest to protect CHF14.6bn R&D firepower.
| Area | 2024 stat | Action |
|---|---|---|
| Alzheimer’s | 55M; >USD1T | Scale/diagnostics |
| Gene/Cell | ~28% CAGR | Selective invest |